Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.
Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...
Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...
CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...
Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...
Growing investments in healthcare infrastructure and advancements in medical research facilities are driving the expansion of ...
Partial heart transplants provide a range of lifesaving options for children with complex congenital heart conditions, and ...
Dr Rajneesh Kapoor highlights the evolution of structural heart disease treatments, exploring the impact of transcatheter ...
Healthcare Asia Magazine on MSN15d
What factors drive the cardiac valve repair devices market in MEA?Mitral valve annuloplasty devices are expected to see the highest growth in the region. Increased investments in healthcare infrastructure, advancements in medical research, and a growing elderly ...
Mitral Valve Stenosis: The valve becomes too narrow, restricting proper blood flow. Think of the mitral valve as a one-way door with two flaps. In regurgitation, the door fails to close tightly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback